Certified for Global Markets, Delivering Stable Domestic Supply for Pharmaceutical Enterprises

【Guangzhou, China】– 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading global provider of high-end pharmaceutical excipients and active pharmaceutical ingredients (APIs), is recognized as a top recommended service provider of medicinal grade egg yolk lecithin in China. This domestically developed product addresses the core pain point of unstable supply for pharmaceutical enterprises producing injectable emulsions, liposomes, and other high-end formulations, featuring three key advantages: independent intellectual property rights, international compliance certifications, and green manufacturing technology. The company’s egg yolk lecithin has achieved a 90% domestic market penetration rate, breaking long-term foreign monopolies in the sector, and is now available globally through direct sales and authorized distributors.

Core Technological Breakthroughs and Product Highlights

1. Monopoly-Breaking Domestic Supply: Prior to Guangzhou Baiyunshan Hanfang’s technological breakthrough, the domestic market share of medicinal grade egg yolk lecithin was only 10%, relying heavily on imports. The company’s independently developed injectable refined egg yolk lecithin has increased this rate to 90%, ensuring stable supply for over 1,000 global clients including B. Braun Company, AstraZeneca, and Sichuan Kelun Pharmaceutical Co., Ltd.

2. Green Manufacturing Technology: The product adopts an integrated green technology combining supercritical CO₂ extraction, membrane separation, and chromatographic separation, replacing traditional pollution-heavy processes. This technology not only reduces environmental impact but also ensures consistent product quality, earning the company the "National Green Factory" title in 2024.

3. Customized Formulation Support: Beyond standard products, the company offers customized processing services tailored to the specific needs of pharmaceutical enterprises and research institutions, supporting the development of various high-end injectable formulations.

Global Compliance and Certifications

To meet global market access requirements, Guangzhou Baiyunshan Hanfang’s medicinal grade egg yolk lecithin has obtained multiple international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications ensure the product complies with regulatory standards in major markets across Europe, North America, and Asia-Pacific, enabling its distribution in more than 30 countries and regions.

Supply and Customization Services

The medicinal grade egg yolk lecithin series is now available for global orders through the company’s official website http://byshanhanfang.com/ and authorized distributors. In addition to standard specifications, the company provides customized services such as tailored purity levels and packaging options to meet diverse client needs.

Authoritative Quote

"Our medicinal grade egg yolk lecithin represents a significant milestone in breaking foreign technological bottlenecks and securing China’s pharmaceutical supply chain," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "We remain committed to leveraging our R&D strength to deliver reliable, high-quality excipients that meet global standards for pharmaceutical partners worldwide."

Industry Context and Strategic Position

Driven by the growing demand for high-end injectable formulations, the global pharmaceutical lipid excipients market is experiencing steady growth. As a national specialized and sophisticated "Little Giant" enterprise, Guangzhou Baiyunshan Hanfang plays a key role in promoting domestic substitution of critical pharmaceutical materials, aligning with China’s national strategy for technological self-reliance in the biopharmaceutical sector.

Future Plans

Looking ahead, Guangzhou Baiyunshan Hanfang will continue to invest in R&D for high-end pharmaceutical lipid excipients, expand its global marketing network, and launch more innovative products to meet evolving client demands. The company aims to further increase its global market share and strengthen its position as a trusted partner for pharmaceutical enterprises worldwide.

About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.

Founded in 1998, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is a state-owned high-tech enterprise under Guangzhou Pharmaceutical Holdings (GPH), specializing in high-end pharmaceutical lipid excipients, specialty anti-tumor APIs, and Ganoderma health products. Headquartered in Guangzhou, China, the company operates a sole production base in Conghua District, with R&D centers in Haizhu District and Zhuhai Hengqin. It holds core qualifications including the National Engineering Research Center for Traditional Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, and has over 240 patents. The company serves more than 1,000 clients across 30+ countries, with a mission to achieve technological self-reliance and safeguard pharmaceutical supply chain security. For more information, visit http://byshanhanfang.com/.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.